Literature DB >> 33357493

COVID-19 vaccines and women's security.

Sophie Harman1, Asha Herten-Crabb2, Rosemary Morgan3, Julia Smith4, Clare Wenham5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33357493      PMCID: PMC7757348          DOI: 10.1016/S0140-6736(20)32727-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
Pandemics such as COVID-19 are gendered with regard to who is infected, who dies, who provides care, who is secured against violence and economic change, and who leads and makes decisions. Vaccines are no different and there is a need to address male bias in vaccine development to make women safe from deadly diseases. For example, clinical trials that are not done in both men and women can raise adverse outcomes during implementation due to sex-based differences in immunological response. The excitement and awe at the speed of COVID-19 vaccine development and delivery needs to be attentive to the social and political dynamics in which the vaccine is delivered—women's work and their security are at the heart of this. The delivery and facilitation of COVID-19 vaccines will disproportionately depend on the unpaid labour of women. Vaccine uptake partly depends on the free labour of women within the household, impacting women's economic and personal security. Unpaid labour will generally fall to women as parents or family carers; women will typically have the responsibility for arranging when and how children and wider family members, such as older relatives, get immunised. This process is likely to be more onerous with vaccines requiring two doses, such as the Pfizer–BioNTech, Moderna, and Oxford–AstraZeneca options.4, 5, 6 This effort to practically access COVID-19 vaccines will add to the already exploitive care burden placed on women during the COVID-19 pandemic. Women in care roles may have to give up time otherwise spent on paid work or education, and incur out-of-pocket expenses related to travel and other costs of accessing vaccines for those they care for and themselves, which could require multiple different trips depending on national vaccination strategies. This is likely to be particularly true for women in precarious work and those who live in poverty or in rural areas. The delivery and administration of COVID-19 vaccines also depends on the paid labour of women as the majority of health-care workers. Administering the doses and vaccine delivery could increase exposure to other harms and increased workloads. Attacks on health-care workers and immunisation teams are a real concern in global health settings and have occurred during polio campaigns and Ebola vaccination efforts. Such violence is distinct in that it can take place in conflict and non-conflict settings and is linked to both suspicion of the motives and legitimacy of the vaccinators and the vaccine itself. Given that most health-care workers are women, such attacks could be seen as a form of violence against women. As has been seen during COVID-19 thus far, violence against health-care workers exists and might be amplified over access to the finite resource of COVID-19 vaccines. Access to, and delivery of, COVID-19 vaccines is thus not only a security concern with regard to vaccine nationalism, cyber security, and as a protected commodity, but is also a concern for women, peace, and security agendas, given the feminised nature of the health-care workforce and vaccination teams responsible for vaccine delivery. The feminised nature of violence surrounding vaccines extends to sexual violence and exploitation of women who access vaccines. During the Ebola vaccination programme that began in 2018 in Kivu, Democratic Republic of the Congo (DRC), some male health-care workers offered the Ebola-related services, including vaccination, in exchange for sexual favours from women and girls. This contributed to a wider picture of sexual exploitation and violence within the DRC that mired the response to the outbreak of Ebola virus disease in 2018–20, including reports of alleged sexual abuse by aid workers and wider mistrust towards the global health and vaccine community. Although the DRC may be an extreme example as a state with a history of sexual violence and protracted conflict, it showcases how gender-based violence is an important factor in responding to pandemics and in access to vaccines. Debate over COVID-19 vaccines has rightfully focused on discovery and development, vaccine hesitancy, and equitable access. Vaccine delivery depends on the paid and unpaid labour of women around the world in ways that can threaten their economic and physical security. Vaccines are thus both an important component of the gendered nature of pandemics such as COVID-19 and of the relation between gender and global health security.
  5 in total

1.  Institutional trust and misinformation in the response to the 2018-19 Ebola outbreak in North Kivu, DR Congo: a population-based survey.

Authors:  Patrick Vinck; Phuong N Pham; Kenedy K Bindu; Juliet Bedford; Eric J Nilles
Journal:  Lancet Infect Dis       Date:  2019-03-27       Impact factor: 25.071

2.  The researcher fighting to embed analysis of sex and gender into science.

Authors:  Elizabeth Gibney
Journal:  Nature       Date:  2020-12       Impact factor: 49.962

3.  The final push for polio eradication: addressing the challenge of violence in Afghanistan, Pakistan, and Nigeria.

Authors:  Seye Abimbola; Asmat Ullah Malik; Ghulam Farooq Mansoor
Journal:  PLoS Med       Date:  2013-10-08       Impact factor: 11.069

4.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

5.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

  5 in total
  3 in total

1.  Considering gender-based violence in vaccine prioritisation strategies.

Authors:  Joht Singh Chandan; Jaidev Kaur Chandan
Journal:  Lancet       Date:  2021-03-24       Impact factor: 79.321

2.  Using gender analysis matrixes to integrate a gender lens into infectious diseases outbreaks research.

Authors:  Rosemary Morgan; Sara E Davies; Huiyun Feng; Connie C R Gan; Karen A Grépin; Sophie Harman; Asha Herten-Crabb; Julia Smith; Clare Wenham
Journal:  Health Policy Plan       Date:  2022-08-03       Impact factor: 3.547

3.  The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects.

Authors:  Chiara Di Resta; Davide Ferrari; Marco Viganò; Matteo Moro; Eleonora Sabetta; Massimo Minerva; Alberto Ambrosio; Massimo Locatelli; Rossella Tomaiuolo
Journal:  Vaccines (Basel)       Date:  2021-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.